Peptide Initiative

Peptides · Peptide comparison

Abarelix vs Degarelix

GnRH Antagonist for Advanced Prostate Cancer Treatment

Fast-acting GnRH antagonist that rapidly lowers testosterone for advanced prostate cancer treatment

  • Hormone Support
  • Hormone Support

At a glance

Quick comparison

Dose rangeAbarelix100–100 mgDegarelix80–80 mg
FrequencyAbarelixOnce dailyDegarelixOnce daily
AdministrationAbarelixIntramuscular injection (depot formulation)DegarelixAs directed by healthcare provider
Cycle lengthAbarelixOngoing/indefiniteDegarelixOngoing/indefinite
Onset speedAbarelixModerate (1-2 weeks)DegarelixModerate (1-2 weeks)
Evidence levelAbarelixStrong human trials (Phase 3 or FDA approved)DegarelixStrong human trials (Phase 3 or FDA approved)

Efficacy

Benefit ratings

Rapid Hormone Control

Abarelix90%
DegarelixNo recorded rating

Advanced Cancer Management

Abarelix86%
DegarelixNo recorded rating

Patient Tolerability

Abarelix83%
DegarelixNo recorded rating

Rapid Testosterone Control

AbarelixNo recorded rating
Degarelix94%

Extended Duration

AbarelixNo recorded rating
Degarelix90%

Clinical Efficacy

AbarelixNo recorded rating
Degarelix87%

Technical data

Compound specifications

Abarelix

Molecular formula
C72H95ClN14O14
Molecular weight
1416.1 g/mol
Half-life
Approximately 13 days
Bioavailability
~100% (intramuscular depot injection)
CAS number
183552-38-7

Degarelix

Molecular formula
C82H103ClN18O16
Molecular weight
1632.3 Da
Half-life
~53 days (median terminal half-life)
Bioavailability
100% (subcutaneous injection)
CAS number
214766-78-6

Protocols

Dosing compared

Abarelix

Intramuscular

  • 100 mgDay 1, 15, 29, then every 4 weeks · Up to 12 months (effectiveness beyond 12 months not established)This is the FDA-approved dose for advanced prostate cancer. A 100 mg shot is given into the buttock muscle on day 1, 15, and 29, then once every 4 weeks. The drug was sold as Plenaxis. [4]

Degarelix

Subcutaneous

  • 240 mg (two 120 mg injections)One time (loading dose) · Single starting doseFDA-approved loading dose for advanced prostate cancer, given as two separate deep injections under the skin of the belly. This rapidly lowers testosterone without the early surge seen with older drugs [1][2].
  • 80 mgEvery 28 days · OngoingFDA-approved maintenance dose, started 28 days after the loading dose. Keeps testosterone at castrate levels in over 97% of patients [1][2].

Applications

Best suited for

Abarelix

Reducing testosterone levels in prostate cancer
Abarelix is particularly well-suited for individuals focused on reducing testosterone levels in prostate cancer. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Slowing cancer progression in advanced disease
Abarelix is particularly well-suited for individuals focused on slowing cancer progression in advanced disease. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Managing hormone-dependent cancer symptoms
Abarelix is particularly well-suited for individuals focused on managing hormone-dependent cancer symptoms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Degarelix

Men with advanced or metastatic prostate cancer requiring rapid hormone control
Degarelix is particularly well-suited for individuals focused on men with advanced or metastatic prostate cancer requiring rapid hormone control. [1][2] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Patients who need immediate testosterone suppression to prevent cancer progression
Degarelix is particularly well-suited for individuals focused on patients who need immediate testosterone suppression to prevent cancer progression. [1][2] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Men who cannot tolerate the initial testosterone surges from GnRH agonists
Degarelix is particularly well-suited for individuals focused on men who cannot tolerate the initial testosterone surges from gnrh agonists. [5][6] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety profile

Side effects

Abarelix

Common

  • Mild discomfort at treatment site
  • Hot flashes and sweating
  • Decreased libido and sexual dysfunction
  • Increased liver enzymes
  • Injection site reactions (pain, redness, swelling)
  • Abdominal pain and gastrointestinal symptoms
  • Headache and dizziness
  • Weight changes
  • Gynecomastia (breast tissue enlargement)
  • Bone density loss with long-term use

Serious

  • Severe allergic reaction

Degarelix

Common

  • Mild discomfort at treatment site
  • Injection site pain (28% of patients)
  • Injection site redness or erythema (17%)
  • Hot flashes (26% experience them)
  • Increased liver enzymes and gamma-glutamyltransferase (10%)
  • Weight gain (9%)
  • Hypertension or elevated blood pressure (6%)
  • Back pain (6%)
  • Chills (5%)
  • Constipation (5%)
  • Urinary tract infection (5%)
  • Injection site swelling (6%)
  • Injection site induration or hardness (4%)
  • Decreased sex drive and erectile dysfunction
  • Gynecomastia (breast tissue growth)
  • Testicular atrophy (shrinking)

Serious

  • Severe allergic reaction

Research status

Safety & evidence

Abarelix

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved in 2003 as PLENAXIS for advanced symptomatic prostate cancer; discontinued and no longer marketed in the US.
Safety overview
Abarelix carries significant safety concerns primarily related to histamine release reactions, which led to its voluntary withdrawal from the U.S. market in 2006. Serious allergic responses including anaphylaxis, flushing, and hypotension have been documented. Long-term use poses substantial risks of bone density loss, cardiovascular effects from hormonal suppression, and metabolic complications including weight gain and altered lipid profiles. Liver enzyme elevations occur in 5-10% of patients. All use requires intensive medical supervision with regular monitoring of testosterone levels, liver function, bone density, and cardiovascular markers.

Contraindications

  • Pregnancy or lactation
  • Severe hypersensitivity reactions to peptide therapeutics
  • History of anaphylaxis with similar compounds

Degarelix

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Degarelix is an FDA-approved GnRH antagonist with safety data from Phase 3 trials and post-market use in prostate cancer treatment. [1][2] Advantages over GnRH agonists include absence of testosterone flare, allowing rapid castration without initial symptom surge. [5][6] Primary safety concerns relate to intentional hormone suppression: hot flashes occur in 40-70% of men, erectile dysfunction in 40-60%, bone density loss of 2-3% annually, [8] and cardiovascular risks in patients >65 years. [9] Injection site reactions (erythema, induration) occur in 20-30% of patients and can be severe in a small percentage. [2] Liver enzyme elevations appear in 5% of patients. [2] QT prolongation potential exists and cardiac monitoring is recommended in susceptible patients. [2]

Contraindications

  • History of severe hypersensitivity to degarelix [2]
  • Allergy to any product components (mannitol or other additives) [2]
  • Active untreated severe anaphylaxis risk

Decision guide

Which is right for you?

Abarelix

Choose Abarelix if…

  • Reducing testosterone levels in prostate cancer
  • Slowing cancer progression in advanced disease
  • Managing hormone-dependent cancer symptoms

Degarelix

Choose Degarelix if…

  • Men with advanced or metastatic prostate cancer requiring rapid hormone control
  • Patients who need immediate testosterone suppression to prevent cancer progression
  • Men who cannot tolerate the initial testosterone surges from GnRH agonists